Overview

A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph

Status:
Terminated

Trial end date:
2017-07-01

Target enrollment:

Participant gender:

Summary

Prospective, open-label, within-patient, multi-center study of Lymphoseek in the detection of lymph nodes in subjects with known cancer of the cervix. All subjects will receive a single dose of 50 µg Lymphoseek radiolabeled with 2 mCi (74 MBq) Tc 99m.

Phase:

Phase 2

Details

Lead Sponsor:

Cardinal Health 414, LLC
Navidea Biopharmaceuticals

Treatments:

Dextrans
Technetium Tc 99m Pentetate